Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19704121 | 0.80 | — | — | |
| SCHEMBL20067718 | 0.80 | — | — | |
| SCHEMBL20351432 | 0.80 | — | — | |
| SCHEMBL14261039 | 0.78 | SLC22A6 (0.35) | TDP1 | |
| SCHEMBL24211177 | 0.77 | — | — | |
| SCHEMBL18856006 | 0.77 | — | — | |
| SCHEMBL11526414 | 0.76 | — | — | |
| SCHEMBL25964290 | 0.75 | — | — | |
| SCHEMBL20404216 | 0.74 | MAOB (0.31) | HSD17B10TDP1 | |
| SCHEMBL25008397 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10675352-B2 | Extracellular targeted drug conjugates | CENTROSE, LLC (US) | 2020-06-09 | — | — | US | disclosed |
| US-9650363-B2 | Integrin antagonist conjugates for targeted delivery to cells expressing LFA-1 | HOFFMANN-LA ROCHE INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9586916-B2 | Integrin antagonist conjugates for targeted delivery to cells expressing alpha-V-beta-3 | HOFFMANN-LA ROCHE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20170049908-A1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | CENTROSE LLC (US) | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10675352-B2 | Extracellular targeted drug conjugates | ENTPD1, ENTPD2, ENTPD3 | HSD17B10 1522/4885TDP1 706/4885 |
| US-20170049908-A1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | ENTPD1, ENTPD2, ENTPD3 | HSD17B10 3666/4885TDP1 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.